PuSH - Publication Server of Helmholtz Zentrum München: Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Demel, U.M.* ; Boger, M.* ; Yousefian, S.* ; Grunert, C.* ; Zhang, L.* ; Hotz, P.W.* ; Gottschlich, A.* ; Köse, H.* ; Isaakidis, K.* ; Vonficht, D.* ; Grünschläger, F.* ; Rohleder, E.* ; Wagner, K.* ; Dönig, J.* ; Igl, V.* ; Brzezicha, B.* ; Baumgartner, F.* ; Habringer, S.* ; Löber, J.* ; Chapuy, B.* ; Weidinger, C.* ; Kobold, S. ; Busse, A.B.* ; Müller, S.* ; Wirth, M.* ; Schick, M.* ; Keller, U.*

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

J. Clin. Invest. 132:e152383 (2022)

Postprint

Research data

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell-mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell-mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Antigen Presentation ; Immunology ; Immunotherapy ; Oncology ; Ubiquitin-proteosome System

ISSN (print) / ISBN 0021-9738

e-ISSN 1558-8238

Journal Journal of Clinical Investigation

Quellenangaben Volume: 132, Issue: 9, Article Number: e152383

Publisher American Society of Clinical Investigation

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)

Grants Deutsche Forschungsgemeinschaft
European Research Council
Wilhelm-Sander foundation
TCR2 Inc.
H2020 Program of the European Union
Arcus Bioscience
Charité – Universitätsmedizin Berlin
Deutsche Krebshilfe
Stiftung Charité
Berlin Institute of Health